ATE453388T1 - Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel - Google Patents

Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel

Info

Publication number
ATE453388T1
ATE453388T1 AT05758830T AT05758830T ATE453388T1 AT E453388 T1 ATE453388 T1 AT E453388T1 AT 05758830 T AT05758830 T AT 05758830T AT 05758830 T AT05758830 T AT 05758830T AT E453388 T1 ATE453388 T1 AT E453388T1
Authority
AT
Austria
Prior art keywords
antiangiogenetic
preparation
medicinal products
calcium trifluoroacetate
trifluoroacetate
Prior art date
Application number
AT05758830T
Other languages
English (en)
Inventor
Rosa Gobbi
Original Assignee
Eureon Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureon Ag filed Critical Eureon Ag
Application granted granted Critical
Publication of ATE453388T1 publication Critical patent/ATE453388T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT05758830T 2004-06-24 2005-06-17 Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel ATE453388T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001279A ITMI20041279A1 (it) 2004-06-24 2004-06-24 Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico
PCT/EP2005/006533 WO2006000339A2 (en) 2004-06-24 2005-06-17 Calcium trifluoroacetate for preparing antiangiogenetic medicaments

Publications (1)

Publication Number Publication Date
ATE453388T1 true ATE453388T1 (de) 2010-01-15

Family

ID=35134535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05758830T ATE453388T1 (de) 2004-06-24 2005-06-17 Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel

Country Status (12)

Country Link
US (1) US20070260088A1 (de)
EP (1) EP1763343B1 (de)
JP (1) JP4903694B2 (de)
AT (1) ATE453388T1 (de)
DE (1) DE602005018642D1 (de)
DK (1) DK1763343T3 (de)
ES (1) ES2339263T3 (de)
IT (1) ITMI20041279A1 (de)
PL (1) PL1763343T3 (de)
PT (1) PT1763343E (de)
SI (1) SI1763343T1 (de)
WO (1) WO2006000339A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007058360B3 (de) * 2007-12-03 2009-04-30 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung einer erhabenen Markierung auf einem Glasgegenstand
EP2796135A1 (de) * 2013-04-22 2014-10-29 Polichem S.A. Verwendung von Trifluoressigsäure und Salzen davon zur Behandlung von Hypercholesterinämie
EP2845591A1 (de) 2013-09-04 2015-03-11 Polichem S.A. Verwendung von Trifluoressigsäure als keratolytischer Wirkstoff zur Behandlung hyperkeratotischer Hautläsionen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880660A (en) * 1987-08-28 1989-11-14 Minnesota Mining And Manufacturing Company Method for priming hard tissue
IT1236512B (it) * 1989-10-06 1993-03-11 Eniricerche Spa Elettrolita polimerico solido a base poliepossidica.
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
IT1317001B1 (it) * 2000-03-13 2003-05-26 Sigma Tau Ind Farmaceuti Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi.
AU2002236476A1 (en) * 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
ITMI20040665A1 (it) * 2004-04-02 2004-07-02 Pharmaproducts Uk Ltd Sale di calcio per il trattamento della psoriasi e di dermatiti

Also Published As

Publication number Publication date
SI1763343T1 (sl) 2010-05-31
WO2006000339A2 (en) 2006-01-05
US20070260088A1 (en) 2007-11-08
EP1763343B1 (de) 2009-12-30
PL1763343T3 (pl) 2010-07-30
DK1763343T3 (da) 2010-05-03
DE602005018642D1 (de) 2010-02-11
ITMI20041279A1 (it) 2004-09-24
PT1763343E (pt) 2010-03-24
EP1763343A2 (de) 2007-03-21
WO2006000339A3 (en) 2006-08-03
JP4903694B2 (ja) 2012-03-28
JP2008503517A (ja) 2008-02-07
ES2339263T3 (es) 2010-05-18

Similar Documents

Publication Publication Date Title
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
NO20082531L (no) Neuropilinantagonister
NZ544472A (en) Compounds and therapeutical use thereof
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
BRPI0510947A (pt) tratamento de doença respiratória
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA201691018A1 (ru) Фармацевтическая композиция, содержащая смесь проферментов и ферментов
UY33219A (es) Cetoenoles cíclicos para terapias
AU306618S (en) A chair
ATE433459T1 (de) Desoxo-nonadepsipeptide
ATE453388T1 (de) Calciumtrifluoroacetat zur bereitung antiangiogenetischer arzneimittel
AU309504S (en) Pen
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
ATE458819T1 (de) Konjugat mit p21-protein zur krebsbehandlung
ATE455789T1 (de) Substituierte nonadepsipeptide
ITMI20040954A1 (it) Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
DE502006002907D1 (de) Verbandsmaterial mit wirkstoffen
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
MD2904G2 (ro) Utilizarea preparatului Gerovital H3 pentru tratamentul afecţiunilor sistemului nervos central la copii
TH84335A (th) แอนติบอดีของ dr5 และการใช้สิ่งนั้น

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1763343

Country of ref document: EP

EEIH Change in the person of patent owner